Celecoxib A Selective COX-2 Inhibitor Mitigates Fibrosis but not Pneumonitis Following Lung Irradiation: A Histopathological Study

(E-pub Ahead of Print)

Author(s): Rasoul Azmoonfar, Peyman Amini, Hana Saffar, Elahe Motevaseli, Ehsan Khodamoradi, Dheyauldeen Shabeeb, Ahmed Eleojo Musa, Masoud Najafi*.

Journal Name: Current Drug Therapy

Become EABM
Become Reviewer

Abstract:

Background: Lung is one of the radiosensitive and late responding organs, and is an important target for ionizing radiation. Radiation-induced pneumonitis and fibrosis are major consequences of lung exposure to a high dose of radiation and pose threats to the lives of exposed people. Mitigation of lung injury following an accidental radiation event or for patients with lung cancer is one of the most interesting issues in radiobiology. In current study, we aimed to determine whether celecoxib, the most common cyclooxygenase-2 (COX-2) inhibitor, is able to mitigate pneumonitis and fibrosis following lung irradiation or not.

Materials and methods: 20 male mice were assigned to 4 groups: control, celecoxib treatment, radiation, and radiation plus celecoxib. Irradiation was performed with a dose of 18 Gy cobalt-60 (60Co) gamma rays. Celecoxib treatment (50 mg/kg) started 24 h after irradiation and continued four times per week for 4 weeks.

Results: Irradiation of lung led to remarkable infiltration of macrophages, lymphocytes, mast cells and neutrophils. Also, a mild increase in fibrosis markers including accumulation of collagen, and alveolar and vascular thickening, was observed. Post-exposure treatment with celecoxib was able to mitigate fibrosis as well as alveolar and vascular changes, however it was unable to mitigate pneumonitis markers.

Conclusion: Celecoxib showed that it may have anti-fibrosis effect following exposure of mice lung to radiation, although it was unable to prevent pneumonitis.

Keywords: Radiation, Celecoxib, Lung, Fibrosis, Inflammation, Pneumonitis

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1574885514666191119124739